ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2025
LncRNA CKMT2-AS1 Promotes Hepatocellular Carcinoma Development Via Sponging miR-142-5p and Targeting IFITM3.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Interferon-induced transmembrane (IFITM) proteins at the tumour-immune interface: A four-axis framework for their context-dependent roles.Clinical and translational medicine · 2026Review
- Long non-coding RNA CKMT2-AS1 serves as a biomarker for osteoarthritis and participates in chondrocyte injury via miR-6720-5p.Journal of orthopaedic surgery and research · 2026Article
- Large Gastric Pyloric Gland Adenoma Treated by Endoscopic Submucosal Dissection.Digestive diseases and sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Hepatocellular carcinoma (HCC) stands as the foremost contributor to cancer-related mortality, underscoring its profound significance in the oncological landscape. This study explores the potential regulatory mechanisms of lncRNA CKMT2-AS1 in the functionality of HCC cells, thereby providing a basis for therapeutic approaches in the treatment of HCC. Materials and Methods: Quantitative polymerase chain reaction (qPCR) was utilized to evaluate the expression of CKMT2-AS1 and miR-142-5p in HCC tissues and cells. The interactions between CKMT2-AS1 and miR-142-5p, as well as the interplay between IFITM3 and miR-142-5p, were confirmed through dual-luciferase assays. To assess the effects of CKMT2-AS1 transfection, alongside the cotransfection of CKMT2-AS1 and miR-142-5p interference plasmids, a series of experiments were conducted utilizing CCK-8 and transwell assays to evaluate changes in proliferation, migration, and invasion of HCC cells. Additionally, qPCR was employed to elucidate the influence of miR-142-5p on the expression of IFITM3 in HCC cells. Results: The study elucidated that CKMT2-AS1 was significantly upregulated in HCC tissues and cells, while miR-142-5p exhibited a marked downregulation, revealing a noteworthy negative correlation. Notably, the downregulation of CKMT2-AS1 hindered the function of HCC cells. Conversely, the downregulation of miR-142-5p effectively mitigated the inhibitory effects of CKMT2-AS1 on cellular activities. Furthermore, the upregulation of miR-142-5p resulted in a substantial decrease in the levels of IFITM3 in HCC cells. This investigation established a potential regulatory network, identifying IFITM3 as the downstream target mRNA. Conclusion: The sponging effect of CKMT2-AS1 on miR-142-5p resulted in altered expression levels of IFITM3, subsequently influencing the progression of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.